Tricida Inc (NASDAQ:TCDA) Director Klaus R. Dr Veitinger sold 3,492 shares of the business’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $36.30, for a total value of $126,759.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Tricida stock opened at $33.23 on Friday. The firm has a 50 day moving average price of $36.29. Tricida Inc has a 1 year low of $19.43 and a 1 year high of $42.80. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.30 and a quick ratio of 8.30. The firm has a market capitalization of $1.66 billion and a P/E ratio of -7.16.
Tricida (NASDAQ:TCDA) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.10). As a group, equities research analysts predict that Tricida Inc will post -3.44 EPS for the current fiscal year.
TCDA has been the subject of several research analyst reports. Needham & Company LLC boosted their target price on ViaSat from $78.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 24th. Goldman Sachs Group initiated coverage on Tricida in a research note on Wednesday, June 26th. They set a “buy” rating and a $48.00 target price for the company. Zacks Investment Research downgraded Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Empire boosted their target price on Tricida from $37.00 to $58.00 in a research note on Monday, April 1st. Finally, Cowen reissued a “buy” rating and set a $50.00 target price on shares of Tricida in a research note on Tuesday, June 25th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $47.00.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Further Reading: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.